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Metaplastic breast cancer (MBC) is a rare subtype of invasive breast cancer that tends to have an aggressive clinical
presentation as well as a variety of distinct histologic designations. Few systemic treatment options are available for
MBC, as it has consistently shown a suboptimal response to standard chemotherapy regimens. These characteristics
result in a worse overall prognosis for patients with MBC compared to those with standard invasive breast cancer.
Due to its rarity, data focusing on MBC is limited. This review will discuss the clinical presentation, breast imaging
findings, histologic and molecular characteristics of MBC as well as potential future research directions.
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Metaplastic breast cancer (MBC) is a rare and histolog-
ically diverse subtype of breast carcinoma. It accounts
for less than 1% of all breast cancers [1,2]. MBC was
not officially recognized as a distinct histologic entity
until 2000, and research on this disease process has
been limited due to its rarity and the variety of tumor
types included in this diagnosis [3]. This category of
breast malignancies encompasses tumors in which
adenocarcinoma is found to co-exist with an admixture
of spindle cell, squamous, chondroid or bone-forming
neoplastic cells [4]. Most metaplastic cancers are estrogen
receptor (ER), progesterone receptor (PR) and Her2-
neu negative [5-7] and tend to have a worse prognosis
than other triple negative breast cancers [4,8-10] with
fewer therapeutic options. In this review, we discuss
the histopathology and clinical features of MBC and
their relevance to prognosis and systemic treatment
options as well as future directions for research.Clinical features
The clinical presentation of MBC has several differences
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stated.(IDC). The median age at time of presentation ranges
in the literature from 48 to 59 years [2,4,7]. MBC more
commonly presents as a rapidly growing mass, and it
has been consistently reported to present larger than
typical breast cancers, generally greater than 2 cm
[2,11-13]. Fixation to the underlying deep tissues or
to the skin has been reported in one study in over
20% of patients [11]. MBC presents with axillary
nodal involvement less frequently than standard invasive
breast cancer, despite the larger tumor size. The incidence
of axillary lymph node metastases spans between 6%
and 26%, [4,14-17] which is substantially lower than
the expected frequency of axillary nodal involvement in
larger invasive breast cancers of greater than 50% [18].
The recommendations for diagnostic imaging are the
same as that for other palpable masses. All palpable
masses should be investigated with both diagnostic
mammography and targeted ultrasound. MBC have been
described as having a high density on mammogram
with either circumscribed, obscured, irregular and/or
spiculated margins. Yang et al. reported a more benign
appearance on mammography including a round or
oval shape and circumscribed margins. The lesions are
often non-calcified [19]. If calcifications are present, the
pattern is amorphous, coarse, punctuate or pleomorphic
[20,21]. Park et al. described a high rate of architectural
distortion associated with MBC [21]. The sonographical Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited. The Creative Commons Public Domain Dedication
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heterogeneous or hypoechoic solid mass or a mixed cystic
and solid mass [19-22]. The complex nature of MBC is
consistent with cystic degeneration and necrosis found on
pathologic evaluation [22,23]. MBC often demonstrate
posterior acoustic enhancement, as opposed to the
posterior shadowing commonly seen with IDC [22].
The MRI features described for MBC are an irregular
mass with speculated margins, often intermediate to
increased T2 signal intensity and isointense or hypointense
on T1 weighted imaging [20,24]. Velasco et al. reported
an increase in T2 hyperintensity in cancers of 91% of
patients with MBC [24]. Although T2 hyperintensity is
often associated with benign lesions, it can be secondary
to necrosis or mucoid production in malignancies.
The incidence of stage IV disease at presentation for
MBC is higher than what is seen with IDC. In one
single institution study, 10.3% of patients with MBC had
metastatic disease at the time of diagnosis, compared
to only 0.9% of patients with IDC [25]. An analysis of
the National Cancer Database from 2006 demonstrated
that patients with MBC were more likely to present
with stage III disease (10.6% vs 8.4%) and stage IV disease
(4.6% vs. 3.4%) when compared to patients with other
invasive breast cancers [26]. An increased risk of local
recurrence (LR) has also been reported in multiple
studies. Rayson et al. noted a 53% risk of LR at 2 years,
consistent with previous studies documenting LR from
35 – 62% in node negative MBC within 5 years of diag-
nosis [4,14-17]. This is significantly higher than the
expected 17 - 20% 5-year LR for other invasive breast
cancers [18]. In one study, age younger than 39, presence
of skin invasion and presence of squamous cell carcinoma
in lymph node metastases significantly increased the
risk for LR and cancer related deaths. The hazard ratios
(HR) for tumor recurrence increased to 14.1, 24.8 and
2.2, whereas the HR for tumor related death increased to
34.4, 39.1 and 5.6 respectively based on these factors [9].
The response of MBC to systemic chemotherapy has
been consistently poor. Neoadjuvant chemotherapy is
minimally effective at reducing tumor burden and pre-
venting progression of disease. Chen et al. reported an
83% progression rate in patients who received neoadjuvant
chemotherapy. This group also found that, in their single
institution retrospective study, no patient responded to
anthracycline, vinorelbine or cyclophosphamide based
regimens and a partial response was noted in 3 of 17
patients with a taxane based regimen (17.6%) [27]. These
results are similar to the MD Anderson Cancer Center
data from 2006 which showed only a 10% complete
response rate in patients with MBC undergoing neoad-
juvant chemotherapy [28]. Efficacy in metastatic disease
is also limited. Cardoso et al. documented a 16.7% response
rate to chemotherapy in metastatic MBC, whereas thatin metastatic IDC was noted to be between 21 and 75%
[29]. Due to the low response rate with chemotherapy,
surgical intervention should be the first step in man-




The term metaplastic carcinoma was first introduced
by Huvos et al. [30]. Histologically, it is a poorly differenti-
ated heterogeneous tumor containing ductal carcinoma
cells admixed with areas of spindle, squamous, chon-
droid, or osseous elements. The wide range of micro-
scopic appearance of MBC has resulted in a variety of
classifications and designations. The World Health
Organization (WHO) classifies MBC into (1) epithelial
type and (2) mixed type [31]. Epithelial-type MBC is,
in turn, classified into (1) squamous cell carcinoma,
(2) adenocarcinoma with spindle cell differentiation,
and (3) adenosquamous carcinoma. Mixed type MBC
is classified into (1) carcinoma with chondroid meta-
plasia, (2) carcinoma with osseous metaplasia, and (3)
carcinosarcoma [31].
The spindle cell subtype, which is the most common,
demonstrates cells forming poorly cohesive sheets of
predominant spindle cell morphology. The spindle cell
component often resembles a low-grade sarcoma or
reactive process such as granulation tissue, which can
be challenging to differentiate [1]. The squamous cell
carcinoma subtype demonstrates infiltrating squamous
carcinoma with polygonal cells, eosinophilic cytoplasm,
and possible keratin pearl formation [1,6]. The carcinosar-
coma contains both malignant epithelium and malignant
stroma [1,22]. The matrix-producing subtype contains
overt carcinoma with a transition to cartilaginous and/
or osseous stromal matrix without a spindle component
[22,32]. MBC with osteoclastic giant cells subtype shows
intraductal or infiltrating carcinoma contiguous or mixed
with spindle cell or sarcomatous stroma plus osteoclastic
cells [1]. See Table 1 for an outlined description of these
classifications according to the WHO.
Tse et al. classified MBC into 3 groups: epithelial-only
carcinoma, biphasic epithelial and sarcomatoid carcinoma,
and monophasic spindle-cell carcinoma [6]. Wargotz
and Norris classified MBC into five subtypes: matrix-
producing carcinoma, squamous cell carcinoma, spindle
cell carcinoma, carcinosarcoma, and metaplastic carcinoma
with osteoclastic giant cells [14,15,18,33,34].
Alternatively, Oberman classified MBC into spindle-cell
carcinoma, invasive ductal carcinoma with extensive
squamous metaplasia, and invasive carcinoma with
pseudosarcomatous metaplasia. He showed a lack of
correlation between the microscopic pattern and the
prognosis. This paper concluded that pathologic sub-
Table 1 World Health Organization histologic classification of metaplastic breast cancer
Epithelial type metaplastic breast cancer Histologic features
Squamous cell carcinoma
Infiltrating squamous carcinoma with polygonal cells, eosinophilic cytoplasm and possible keratin
pearl formation.
Adenocarcinoma with spindle cell differentiation Poorly cohesive sheets of predominant spindle cell morphology; resembles a low grade sarcoma.
Adenosquamous carcinoma
Glands display varying degrees of squamous differentiation, characterized by pavement-like
architecture, prominent intercellular bridges and, to a lesser extent, keratin formation.
Mixed-type metaplastic breast cancer Histologic features
Carcinoma with chondroid metaplasia Immunoreactive for S-100, patchy for cytokeratin while being negative for smooth muscle antigen.
Carcinoma with osseous metaplasia Infiltrating carcinoma with osseous differentiation of the mesenchymal component.
Carcinosarcoma Infiltrating carcinoma with a malignant mesenchymal component.
Adapted from Tavassoli FA, Devilee P: World Health Organization classification of tumors: tumors of the breast and female genital organs. Pathology and genetics
of tumors of the digestive system. In World Health Organization Classification of Tumors. Lyon, France: IARC Press; 2003:37-41 [33].
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should be considered as one entity [35].
Molecular/genetic features
Classically, MBC is biphasic and contains both a car-
cinomatous component (CC) and a heterogeneous sar-
comatous component (HSC). Whether the HSC in a
single case are all derived from a common precursor is
unknown, and whether this precursor is identical to
that of the CC is still controversial. Three major theories
have been proposed to explain the co-existence of biphasic
components [36]. In the collision theory for a biclonal
origin, synchronous growth of the CC and HSC from
separate progenitor cells collide to form one tumor. In the
combination theory for a monoclonal origin, a common
multipotential progenitor cell gives rise to both the CC
and the HSC. In the conversion/metaplastic theory for
a monoclonal origin, the HSC are derived from the CC
through a conversion or metaplastic process.
The presence of transitional areas and epithelial differ-
entiation, such as tight junctions or desmosomes in some
HSC supports a metaplastic process [37]. Additionally, the
co-expression of S-100 (a myoepithelial marker), vimentin
(a mesenchymal marker), and/or cytokeratin (an epithelial
marker) in both the CC and the HSC is also evidence
for a metaplastic process [38]. These findings suggest
that the HSC have an epithelial or myoepithelial origin
and undergo subsequent metaplastic changes, but de-
finitive genetic evidence for a monoclonal origin is still
very limited [36,39,40].
p53 is a nuclear protein with a tumor suppressor
function related to sequence-specific DNA binding and
repair of damaged DNA. Wild-type p53 has a short
half-life and is not detected by immunohistochemistry
(IHC), whereas mutant p53 is stable and detectable by IHC.
Non-mutational stabilization of p53 with overexpression
has also been demonstrated by IHC. The frequencies
of p53 mutations and overexpression are both around
20–40% in conventional breast cancer [41-45]. In
MBC, even though there is currently no data on thefrequency of p53 mutations, the frequency of p53
overexpression may be as high as 61%, suggesting the
involvement of p53 in the pathogenesis of MBC [38]. In
addition, p53 alterations might be part of the mechanism
underlying the morphological progression of MBC from
ductal carcinoma in situ (DCIS) to CC and HSC [46]. In
one study, all evaluated biphasic MBC showed concordant
and equivalent staining for p53 between the CC and
the HSC. The rate of concordance (100%) is higher than
that previously reported (64%) for MBC [47]. Further
evaluation of the p53 gene mutation status of CC and
HSC revealed four mutations, one in each case. For
these four cases, identical mutations between the CC
and the HSC were found. Additionally, there were also
identical mutations between DCIS, CC, and HSC in
one case with an available DCIS component. This
result provides strong and convincing evidence of the
monoclonality not only between CC and each of the
HSC, but also among the DCIS, invasive cancer, and
HSC of MBC, since it would be extremely unlikely for
these morphologically different tumor components to
share identical point mutations if they were from different
progenitor cells [47].
The fact that identical p53 point mutations have been
identified in both stromal and epithelial components in
metaplastic carcinomas in not only breast but also urinary
bladder and uterus suggest that the combination or
conversion theories, which are not mutually exclusive,
are the prime modes of histogenesis of neoplasms in
these organs [48,49]. There are immunohistochemical
and molecular studies that support the hypothesis that
the epithelial component is actually the driving force
behind the high proliferation rate in these metaplastic
carcinomas. For example, vascular endothelial growth
factor expression [50] and matrix metalloprotease 7,
[51] both of which contribute to invasiveness of tumor,
were much more highly expressed in the epithelial aspect
of carcinosarcomas.
In one study, transcriptional profiling was performed
using half-a-genome oligonucleotide microarrays to elu-
Table 2 Potential drug targets for directed therapy
against metaplastic breast cancer











PI3K/AKT pathway PI3 kinase
Protein kinase 3 (Akt)
Mammalian target of
rapamycin (mTOR)
Epithelial growth factor pathway Epithelial growth factor
receptor (EGFR)
Adapted from Hennessy et al. Biphasic metaplastic sarcomatoid carcinoma of
the breast. Ann Oncol. 2006, 17:605–613 [28].
Sebolt-Leopold. Development of anticancer drugs targeting the MAP kinase
pathway. Oncogene. 2000, 19:6594-6599 [69].
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those of IDC using discarded specimens of 4 MBC and
34 IDC. Unsupervised clustering disclosed distinctive
expression profiles between MBC and IDC. Supervised
analysis identified gene signatures discriminating MBC
from IDC as well as between MBC subclasses. Notably,
many of the discriminator genes were associated with
down regulation of epithelial phenotypes, and with syn-
thesis, remodeling and adhesion of extracellular matrix.
Some of them have known or inferred roles related to
Epithelial-Mesenchymal transition (EMT). Importantly,
several of the discriminator genes were upregulated in
a mutant Snail-transfected MCF7 cell known to exhibit
features of EMT, thereby indicating a crucial role for
EMT in the pathogenesis of MBC. In addition, the
identification of SPARC and vimentin as poor prog-
nostic factors have reinforced the role of EMT in
cancer progression [52]. The use of certain microRNAs,
most notably miR-200f, has also been described. This
microRNA is an important modulator of EMT and is
found in low levels in MBC. The substantial decrease in
miR-200f expression levels was found to be accompanied
by an upregulation of EMT transcriptional inducers,
further demonstrating the association between EMT
and MBC [53]. This finding has been supported by the
work of Hayes et al. which showed evidence of Wnt
pathway activation, which results in EMT, in nearly all
primary metaplastic carcinomas [54].
By transcriptional profiling, MBC is characterized by
low expression of GATA3-regulated genes and of genes
responsible for cell-cell adhesion with enrichment for
markers linked to stem cell function and EMT. In contrast
to other breast cancers, most MBC showed a significant
similarity to a “tumorigenic” signature defined using
CD44+/CD24− breast tumor–initiating stem cell–like
cells. MBC is enriched in EMTand stem cell–like features,
and may arise from an earlier, more chemoresistant
breast epithelial precursor than basal-like or luminal
cancers [55]. PIK3CA mutations, EMT, and stem cell-like
characteristics likely contribute to the poor outcomes
of MBC and further highlight the need for novel thera-
peutic targets [55].
Several authors have demonstrated that MBC consist-
ently harbor a basal/myoepithelial phenotype, therefore
suggesting that they may be part of the morphological
spectrum of ‘basal-like’ breast carcinomas [56-62]. One
of the defining features of basal-like breast cancer is
epidermal growth factor receptor (EGFR) overexpres-
sion [63,64]. Studies have shown that MBC consistently
overexpress EGFR but usually lack Her2-neu overex-
pression and amplification [65-67]. Even though MBC
are reported to harbor EGFR overexpression in up to
80% of cases, EGFR gene amplification is the underlying
genetic mechanism in up to one-third of cases. Given thatMBC are poorly responsive to conventional chemotherapy
or hormone therapy regimens and that tumors with EGFR
amplification are reported to be sensitive to EGFR tyrosine
kinase inhibitors, these findings indicate that further
studies are warranted to explore EGFR tyrosine kinase
inhibitors as potential therapeutic agents for metaplastic
breast carcinomas harboring amplification of 7p11 [65,68].
The potential drug targets that could be used for devel-
opment of more directed therapy for metaplastic breast
cancer are listed in Table 2.
Future directions
Research investigating the development of novel systemic
therapeutic regimens is paramount. Studies focusing
on finding new molecular markers would allow for the
creation of clinical trials, especially in the setting of
metastatic disease. Unveiling biological prognostic factors
for MBC would also advance our understanding of the
progression of this aggressive disease.
The observation that MBCs seem to represent a subset
of tumors enriched in EMT and cancer stem-cell (CSC)
characteristics, may account for their resistance to ther-
apy and propensity to metastasize [55]. Like tumors
that arise from CSCs, MBC display high activation of
phosphoinositide 3-kinase (PI3K) pathway components
and commonly carry mutations in PI3K or loss of phos-
phatase and tensin homolog (PTEN) [55]. MBCs also
show strong correlation with a CSC-derived genomic
profile that is heavily weighted for PI3K activity. Like
CSC-derived tumors, most MBCs also display high
levels of angiogenesis and commonly express VEGF and
HIF-1α [70-72]. In vitro studies have demonstrated that
treatment with mTOR inhibitors, such as temsirolimus,
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1 and vascular endothelial growth factor, which further
enhances the effects of inhibition of vasculogenesis by
bevacizumab [73-76]. This and other agents targeted
against these receptors or pathways could potentially be
an area of further research to develop novel therapeutic
options for patients with MBC [76].
Conclusions
MBC is a rare subtype of invasive breast cancer that
accounts for less than 1% of all diagnoses. It is charac-
terized by a larger tumor size at presentation, lower
rates of axillary nodal involvement, higher rates of
both local and distant recurrence, higher rates of ER,
PR and Her2 negativity as well as a sub-optimal
response to systemic therapies when compared to
other invasive breast cancers. Further research studies
will be required to develop targeted treatments with
the goal of improving clinical outcomes.
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